Mackowiak M, Maki J, Motes-Kreimeyer L, Harbin T, Van Kampen K
Merial, Limited, Athens, Georgia 30601, USA.
Adv Vet Med. 1999;41:571-83. doi: 10.1016/s0065-3519(99)80043-3.
The impact of recombinant technology in veterinary and human medicine can only be hypothesized at this time. The development of vaccines and other biological products that go beyond the abilities of conventional products demonstrates the benefits of this new technology. Raboral V-RG was developed as an alternative rabies vaccine with the novel attribute of being effective by the oral route. Within 10 years after its first application as an experimental vaccine in European, red foxes it developed into a useful tool and is being used to curtail rabies epizootics in three wildlife species in the United States. The use of this vaccine can be considered as monumental in contributing to the control of rabies in species that were at one time considered to be incapable of vaccination in large-scale campaigns.
目前，重组技术在兽医和人类医学中的影响只能进行推测。开发出超越传统产品能力的疫苗和其他生物制品，证明了这项新技术的益处。拉博拉尔V-RG作为一种替代狂犬病疫苗而被研发出来，具有口服有效这一新颖特性。在欧洲作为实验性疫苗首次应用于赤狐后的10年内，它发展成为一种有用的工具，并正被用于控制美国三种野生动物物种中的狂犬病流行。这种疫苗的使用可被视为在助力控制狂犬病方面具有里程碑意义，而这些物种曾一度被认为无法在大规模疫苗接种行动中进行免疫。
